Assays that predict a cancer patient’s response (sensitivity or resistance) to a specific treatment improve diagnosis and treatment and ultimately, quality of life.  Prostate cancer (PCa) accounts for 11% of all cancer types among North American men. Enzalutamide and Abiraterone are the two major hormonal therapies for PCa.  Both of these hormones prevent the binding of a steroid (androgen) to its protein receptor (androgen receptor, AR).   Resistance to these hormonal therapies has been recently linked to an androgen receptor variant named AR-V7.  We are developing a nanomaterial enhanced sandwich immunoassay for AR-V7 in the blood of prostate cancer patients.  Highly sensitive detection will be driven by the optical properties of noble metal nanoparticles.  The biomarker will be captured onto a chip containing specific antibodies and subsequently labeled for detection by antibody coated silver nanoparticles.  The relationship between the number of nanoparticles on the chip and the presence and amount of AR-V7 will be established.   We will describe our efforts to incorporate biogenic spherical silver metal NPs, produced by the fungus <i>Fusarium oxysporum</i>, as plasmonic labels for enhanced spectroscopy detection.  Biogenic silver NPs are stabilized with a surface corona that is unique relative to their chemically prepared counterparts.  This method produces particles that contain a native biological scaffold surrounding the nanoparticles that provides enhanced stability and enables facile antibody attachment.  Measurement of the number of nanoparticles that bind to the chip will be accomplished using surface-enhanced Raman scattering (SERS) which provides a unique chemical fingerprint of the label.  Raman spectroscopy (e.g. SERS) is emerging as a technique that can be translated into the diagnostic clinic as a sensitive method that provides rich biochemical information in real-time, non-invasively, and in an automated manner.   Furthermore, the biomarker will be measured in blood or urine and will not require an invasive tissue biopsy.

SERS based predictive assay for the treatment of prostate cancer

255th National Meeting (2018)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.